Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKG315 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT05509985Phase 1Unknown
- Sponsor
- AskGene Pharma
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASKG315 in solid tumor (advanced stage) (2 arms), sponsored by AskGene Pharma. Primary endpoint: Safety (DLTs, AEs, ECG) at 21 days. Status: unknown.
02
Drugs
ASKG315
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05509985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509985.